Earnings results expected in 32 days
Summary
ITCI trading today lower at $131.87, a decrease of -0.04% from yesterday's close, completing a monthly decrease of -0.02% or $0.03. Over the past 12 months, ITCI stock gained 56.69%.
ITCI is not paying dividends to its shareholders.
The last earnings report, released on Feb 20, 2025, missed the consensus estimates by -0.05%. On average, the company has fell short of earnings expectations by -0.03%, based on the last three reports. The next scheduled earnings report is due on May 05, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track ITCI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ITCI Chart
Intra-Cellular Therapies Inc Dividends
ITCI is not paying dividends to its shareholders.
Intra-Cellular Therapies Inc Earnings
| 5 May 2025 (32 Days) Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
ITCI is not paying dividends to its shareholders.
| 5 May 2025 (32 Days) Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Oct 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
Intra-Cellular Therapies Inc (ITCI) FAQ
What is the stock price today?
The current price is $131.87.
On which exchange is it traded?
Intra-Cellular Therapies Inc is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is ITCI.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 7.05B.
What is the earnings per share?
The EPS is -0.32.
When is the next earnings date?
The next earnings report will release on May 05, 2025.
Has Intra-Cellular Therapies Inc ever had a stock split?
No, there has never been a stock split.
Intra-Cellular Therapies Inc Profile
| Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Dr. Sharon Mates Ph.D. CEO | NASDAQ (NGS) Exchange | US46116X1019 ISIN |
| US Country | 610 Employees | - Last Dividend | - Last Split | 7 Jan 2014 IPO Date |
Overview
Intra-Cellular Therapies, Inc. is a forward-looking biopharmaceutical company engaged in the innovative realm of developing small molecule drugs aimed at fulfilling the unmet medical needs within neuropsychiatric and neurological disorders. By focusing on the intricate mechanisms of intracellular signaling within the central nervous system (CNS), the company pioneers in addressing some of the most challenging conditions affecting mental health today. Founded in 2002 and based in New York, New York, Intra-Cellular Therapies is at the forefront of bringing novel treatments from the laboratory to the clinic, with an emphasis on the U.S. market.
Products and Services
- CAPLYTA (Lumateperone) - Currently offered for the treatment of schizophrenia and bipolar depression in adults, CAPLYTA represents Intra-Cellular Therapies’ commitment to addressing severe mental illnesses with a need for better treatment options.
- Lumateperone - Beyond its approved uses, Lumateperone is in a Phase 3 clinical trial stage aiming to expand its application to treat various depressive disorders. This exploration highlights the company’s continuous efforts to broaden the therapeutic utility of its lead compound.
- Lenrispodun (ITI-214) - In development for the treatment of Parkinson's disease, CNS conditions, and other disorders, Lenrispodun exemplifies the company’s venture into addressing neurological disorders with significant unmet needs.
- ITI-1284 - Targeted for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia, ITI-1284 reflects Intra-Cellular Therapies’ dedication to combating the challenges faced by aging populations.
- ITI-333 - This compound is under development for an array of conditions, including substance use disorders, pain, and psychiatric comorbidities such as depression, anxiety, and sleep disorders. ITI-333 embodies the company’s holistic approach to tackling complex, intertwined health issues.
Contact Information
Address: 430 East 29th Street, New York, NY, United States, 10016
Phone: 646 440 9333
2025 © Marketlog. All Rights Reserved.
